Microbubbles as drug delivery systems in cerebrovascular diseases

Recent Patents on Cardiovascular Drug Discovery

Volumn 4, Issue 3, 2009, Pages 222-233

  Spinelli, Mariacarmela ^a   Demitri, Christian ^b   Sannino, Alessandro ^b   Peruzzotti Jametti, Luca ^a,c   Bacigaluppi, Marco ^a,c   Comi, Giancarlo ^a   Corea, Francesco ^a,d  

^a Obstetrics and Gynaecology Department   (Italy)

^b UNIVERSITY OF SALENTO   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

Author keywords

Contrast agent; Drug delivery; Gene therapy; Microbubbles; Molecular imaging; Site targeted therapy; Ultrasonography

Indexed keywords

ALBUMIN; ALBUNEX; CONTRAST MEDIUM; ECHO CONTRAST MEDIUM; FIBRINOLYTIC AGENT; FLUOROCARBON; MRX 815; PERFLEXANE; PERFLUTREN; PHOSPHOLIPID; PLACEBO; POLYMER; SHU 508; SONOVUE; SULFUR HEXAFLUORIDE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ARTERY THROMBOSIS; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DOPPLER ECHOGRAPHY; DRUG DELIVERY SYSTEM; ENCAPSULATION; HUMAN; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MICROBUBBLE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SCANNING ELECTRON MICROSCOPY;

EID: 76149098934     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489009789152221     Document Type: Review

References (72)

1. Feinstein SB, Ten Cate FJ, Zwehl W. Two-dimensional contrast echocardiography. I. in vitro Development and quantitative analysis of echo contrast agents. J Am Coll Cardiol 1984; 3(1): 14-20.
2. Feinstein SB. The powerful microbubble: From bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond. Am J Physiol Heart Circ Physiol 2004; 287(2): H450-H457.
3. Feinstein SB. Contrast ultrasound imaging of the carotid artery vasa vasorum and atherosclerotic plaque neovascularization. J Am Coll Cardiol 2006; 48(2): 236-243.
4. Hansberg T, Wong KS, Droste DW, Ringelstein EB, Kay R. Effects of the ultrasound contrast-enhancing agent Levovist on the detection of intracranial arteries and stenoses in Chinese by transcranial Doppler ultrasound. Cerebrovasc Dis 2002; 14(2): 105-108.
5. Alexandrov AV, Wojner AW, Grotta JC. CLOTBUST Investigators. CLOTBUST: Design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke. J Neuroimaging 2004; 14(2): 108-112.
6. Alexandrov AV, Demchuk AM, Burgin WS, Robinson DJ, Grotta JC. CLOTBUST Investigators. Ultrasound-enhanced thrombolysis for acute ischemic stroke: Phase I. Findings of the CLOTBUST trial. J Neuroimaging 2004; 14(2): 113-117.
7. Cosgrove D. Ultrasound contrast agents: An overview. Eur J Radiol 2006; 60(3): 324-330.
8. Klibanov AL. Ultrasound molecular imaging with targeted microbubble contrast agents. J Nucl Cardiol 2007; 14: 876-884.
9. Bilotta F, Fiorani L, Lendaro E, et al. Pulmonary transit of sonicated albumin microbubbles during controlled mechanical ventilation: A transthoracic echocardiographic study. Anesth Analg 1999; 89(2): 273-277.
10. Calliada F, Campani R, Bottinelli O. Ultrasound contrast agents basic principles. Eur J Radiol 1998; 27: S157-S160.
11. Te Haar GR. Ultrasonic contrast agents: Safety considerations reviewed. Eur J Radiol 2002; 41(3): 217-221;
12. Liu Y. Encapsulated ultrasound microbubbles: Therapeutic application in drug/gene delivery. J Control Release 2006; 114: 89-99.
13. Chomas JE, Dayton P, Allen J, Morgan K, Ferrara KW. Mechanisms of contrast agent destruction. IEEE Trans: Ultrason Ferroelectr Freq Control 2001; 48: 232-248.
14. Chomas JE, Dayton PA, May D, Allen J, Klibanov A, Ferrara K. Optical observation of contrast agent destruction. Appl Phys Lett 2000; 77: 1056-1058.
15. Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1153-1166.
16. Feinstein, S.B.: US4774958 (1988).
17. Feinstein SB, Cheirif J, Ten Cate FJ, et al. Safety and efficacy of a new transpulmonary ultrasound contrast agent: Initial multicenter clinical results. J Am Coll Cardiol 1990; 16(2): 316-324.
18. Widder, K. J., Westkaemper, P.J.: US4844882 (1989).
19. Keller MW, Glasheen W, Kaul S. Albunex: A safe and effective commercially produced agent for myocardial contrast echocardiography. J Am Soc Echocardiogr 1989; 2(1): 48-52.
20. Chang PH, Shung KK, Levene HB. Quantitative measurements of second harmonic Doppler using ultrasound contrast agents. Ultrasound Med Biol 1996; 22(9): 1205-1214.
21. Smith MD, Elion JL, McClure RR, Kwan OL, DeMaria AN. Left heart opacification with peripheral venous injection of a new saccharide echo contrast agent in dogs. J Am Coll Cardiol 1989; 13(7): 1622-1628.
22. Weissman NJ, Cohen MC, Hack TC, Gillam LD, Cohen JL, Kitzman DW. Infusion versus bolus contrast echocardiography: A multicenter, open-label, crossover trial. Am Heart J 2000; 139(3): 399-404.
23. Pelura TJ. Clinical experience with AF0150 (Imagent US), a new ultrasound contrast agent. Acad Radiol 1998; 5 (Suppl 1): S69-S71; discussion S72-S74.
24. Schneider M. SonoVue, a new ultrasound contrast agent. Eur Radiol 1999; 9 (Suppl 3): S347-348.
25. Bleeker H, Shung K, Barnhart J. On the application of ultrasonic contrast agents for blood flowmetry and assessment of cardiac perfusion. J Ultrasound Med 1990; 9: 461-471.
26. Agati L, Renzi M, Sciomer S. Transesophageal dipyridamole echocardiography for diagnosis of coronary artery disease. J Am Coll Cardiol 1992; 19: 765-770.
27. Voci P, Bilotta F, Reale A. Echocardiography. In: Dagianti A, Feigenbaum H, Eds. Excerpta Medica: Amsterdam 1990: 255-260.
28. Voci P, Bilotta F, Scibilia G. in vitro Development and clinical applications of sonicated echocotrast agents. Am J Card Image 1991; 5: 192-199.
29. Sutton, A.D., Johnson R.A., Senior, P.J., Heath, D.: WO9218164 (1992).
30. Schneider, T., Roessling, G., Sachse, A.: WO9408626 (1994).
31. Johnson, R.A., De Jong, N., Van der Wouw, P.A.: US20006017310 (2000).
32. Frinking, P.J.A., Cespedes, I.E., De Jong, N.: US20046726629 (2004).
33. Ten Cate FJ, Drury KJ, Meerbaum S, Noordsy J, Feinstein SB, Shah PM. Myocardial contrast two-dimensional echocardiography: experimental examination at different coronary flo levels. J Am Coll Cardiol 1984; 13: 219-226.
34. Kaul S. Clinical applications of myocardial contrast echocardiography. Am J Cardiol 1992; 69: 46H-64H.
35. Voci P, Bilotta F, Merialdo P, Agati L. Myocardial contrast enhancement after intravenous injection of sonicated albumin microbubbles: A transesophageal echocardiography dipyridamole study. J Am Soc Echocardiogr 1994; 7(4): 337-346.
36. Shapiro JR, Reisner SA, Lichtemberg GS, Meltzer RS. Intravenous contrast echocardiography with the use of sonicated albumin in humans: Systolic disappearance of left ventricular contrast after transpulmonary transmission. J Am Coll Cardiol 1990; 16: 1603-1607.
37. Farnard JR, Puddington IE. Preparation of hollow spherical particles. Powder Technol 1979; 22: 11-16.
38. Schneider M, Bussat P, Barrau MB, et al. A new ultrasound contrast agent based on biodegradable polymeric microballons. Invest Radiol 1991; 26: 190-191
39. Schneider M, Bussat P, Barrau MB, et al. Polymeric microballons as ultrasound contrast agents physical and ultrasonic properties compared with sonicated albumin. Invest Radiol 1992; 27: 134-139.
40. Hasik MJ, Kim DH, Howle LE, Needham D, Prush DP. Evaluation of synthetic phospholipid ultrasound contrast agents. Ultrasonics 2002; 40: 973-982
41. Lepper W, Belcik T, Wei K, et al. Myocardial contrast echocardiography. Circulation 2004; 109: 3132-3135.
42. Dugstad, H., Klaveness, J., Rongved, P., Skurtveit, R., Braenden, J.: US20016221337 (2001).
43. Igartua M, Hernandez RM, Esquisabel A, et al. Influence of formulation variables on the in vitro release of albumin from biodegradable microparticulate systems. J Microencapsul 1997; 14: 349-356.
44. Osborne, N., Sutton, A.D., Johnson, R.A.: US20036623722 (2003).
45. Wheatley, M.A., Lewandowski, J.: US20090028797 (2009).
46. Ottoboni, T.B., Short, R.E., Yamamoto, R.K.: US20090081130A1 (2009).
47. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release 2003; 90: 261-280.
48. Reinhardt M, Hauff P, Briel A, et al. Sensitive particle acoustic quantification (SPAQ): A new ultrasound-based approach for the quantification of ultrasound contrast media in high concentrations. Invest Radiol 2005; 40: 2-7.
49. Casciaro S, Palmizio ER, Conversano F, Demitri C, Distante A. Experimental investigations of nonlinearities and destruction mechanisms for an experimental phospholipid-based ultrasound contrast agent. Invest Radiol 2007; 42: 95-104.
50. Demitri C, Sannino A, Conversano F, Casciaro S, Distante A, Maffezzoli A. Hydrogel based tissue mimicking phantom for in vitro ultrasound contrast agents studies. J Biomed Mater Res B Appl Biomater 2008; 87: 338-345.
51. Jakobsen JA, Oyen R, Thomsen HS, Morcos SK. Safety of ultrasound contrast agents. Eur Radiol 2005; 15: 941-945.
52. Trubestein G. Removal of intravascular thrombi by means of ultrasonics. Experimental study with a new method and its clinical use. Fortschr Med 1978; 96: 755-760.
53. Wu Y, Unger EC, McCreery TP, et al. Binding and lysing of blood clots using MRX-408. Invest Radiol 1998; 33(12): 880-885.
54. Tachibana K, Tachibana S. Albumin microbubble echo-contrast material as an enhancer for ultrasound accelerated thrombolysis. Circulation 1995; 92: 1148-1150.
55. Porter TR, LeVeen RF, Fox R, Kricsfeld A, Xie F. Thrombolytic enhancement with perfluorocarbon-exposed sonicated dextrose albumin microbubbles. Am Heart J 1996; 132: 964-968.
56. Molina CA, Ribo M, Rubiera M, et al. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 2006; 37: 425-429.
57. Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1153-1166.
58. Eggers J, Koch B, Meyer K, et al. Effect of ultrasound on thrombolysis of middle cerebral artery occlusion. Ann Neurol 2003; 53: 797-800.
59. Daffertshofer M, Gass A, Ringleb P, et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: Increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: Results of a phase II clinical trial. Stroke 2005; 36(7): 1441-1446.
60. Unger EC, Porter T, Culp W, Labell R, Matsunaga T, Zutshi R. Therapeutic applications of lipid-coated microbubbles. Adv Drug Deliv Rev 2004; 56(9): 1291-1314.
61. Tsutsui JM, Xie F, Cano M, et al. Detection of retained microbubbles in carotid arteries with real-time low mechanical index imaging in the setting of endothelial dysfunction. J Am Coll Cardiol 2004; 44(5): 1036-1046.
62. Marsh JN, Senpan A, Hu G, et al. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomed 2007; 2(4): 533-543.
63. Davson H, Segal MB. Physiology of the CSF and blood-brain barriers. CRC Press: Boca Raton, FL, USA 1996.
64. Banks WA. Is obesity a disease of the blood-brain barrier? Physiological, pathological, and evolutionary considerations. Curr Pharm Des 2003; 9: 801-809.
65. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 2004; 89: 807-811.
66. Pan W, Kastin AJ. In: Sharma HS, Westman J, Eds. Blood-spinal cord and brain barriers in health and disease. Chapter 20: Transport of cytokines and neurotrophins across the blood-brain barrier and their regulation after spinal cord injury. Elsevier, Amsterdam: The Netherlands 2004: 395-407.
67. Patrick JT, Nolting MN, Goss SA, et al. Ultrasound and the blood-brain barrier. Adv Exp Med Biol 1990; 267: 369-381.
68. Ng KY, Cho CW, Henthorn TK, Tanguay RL. Effect of heat preconditioning on the uptake and permeability of R123 in brain microvessel endothelial cells during mild heat treatment. J Pharm Sci 2004; 93(4): 896-907.
69. Reinhard M, Hetzel A, Krüger S, et al. Blood-brain barrier disruption by low-frequency ultrasound. Stroke 2006; 37(6): 1546-1548.
70. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR Imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001; 220(3): 640-646.
71. Kopechek JA, Abruzzo TM, Wang B, et al. Ultrasound-mediated release of hydrophilic and lipophilic agents from echogenic liposomes. J Ultrasound Med 2008; 27(11): 1597-1606.
72. Shaw GJ, Meunier JM, Huang SL, Lindsell CJ, McPherson DD, Holland CK. Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes. Thromb Res 2009 [Epub ahead of print].